The tariff classification of a high-pressure syringe set from Malaysia
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated September 25, 2026, you requested a tariff classification ruling. Additional information was provided via email. The imported product is a high-pressure syringe set, model REF 200111.The complete syringe set is housed in a blister tray, which consists of a barrel, a plunger assembly, a coiled tube, a fill tube, a long spike and dust caps.
The high-pressure syringe is intended to be used with a contrast media injector to deliver contrast media and/or saline within the area of Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Digital Subtraction Angiography (DSA). As you state, the high-pressure syringe is for single use only.
Additionally, it is intended for use by trained healthcare professionals including physicians, radiologists, nurses, and other qualified medical personnel, in hospitals, diagnostic imaging centers and other healthcare facilities.
The applicable subheading for the a high-pressure syringe set, model REF 200111, when imported into the United States, will be 9018.31.0080, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Instruments and appliances used in medical, surgical, dental or veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments; parts and accessories thereof: Syringes, needles, catheters, cannulae and the like; parts and accessories thereof: Syringes, with or without their needles: Other.” The general rate of duty will be Free.
As you indicate, all raw materials, including plastic resin and color masterbatch, are imported from China. In Malaysia, these raw materials are processed to manufacture the individual components and then subsequently assembled into the finished high-pressure syringe product.
Manufacturing and processing operations performed in Malaysia include raw-material preparation; extrusion tube forming and processing; injection molding of raw materials into high-pressure syringe components, including barrels, plungers, protective caps, connectors, long spikes, and dust caps; component assembly; adhesive bonding; printing; inspection; blister packaging and sealing; ethylene oxide sterilization; aeration; finished-product inspection; and storage and preparation for shipment.
When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018. The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982).
This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993). Additionally, Section 304 of the Tariff Act of 1930, as amended (19 U.S.C.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N365408).